Andrew Howden is a senior executive and company director with over 30 years of experience in pharmaceuticals and healthcare across Asia, Australia, and Europe. He has held leadership roles at various companies, including IMS Health, AstraZeneca, Quintiles Transnational, and iNova Pharmaceuticals, and currently serves on the boards of several companies. Howden has extensive experience in strategic leadership, mergers and acquisitions, business growth, and developing high-performing teams across cultures.

1. Andrew Howden
B.Sc. M.Com. GAICD
E andrewjhowden@hotmail.com
M +61 (0) 422 447 442
M anl y
1 3 Bower St,
Manly,
NSW 2095
Australia
Senior executivewith broad global experiencein the Pharmaceutical and healthcare industry.
Extensive leadership and strategic skills to drive market leading results from senior management
teams across numerous cultures in Asia, Australiaand Europe. Board level experience as
Chairman, CEO and Director for listed and Private Equity owned companies across Asia and
Australia. Graduate ofAustralian Institute ofCompany Directors.
Current Directorships
First Pharma P/L – Executive Chairman Australian ow ned pharmaceuticalcompany (startup)
created by pharma executives and PE Investors
Sept 2016 - present
The True Origins CompanyP/L - Chairman Australian company providing high value, innovative
nutritional health food, beverages and w ellbeing
products through the ow nership of a clean, naturaland
quality trusted ingredient source.
June 2016 - present
Aslan Pharmaceuticals Ltd - Director Singapore based Biotech. Independent Director.
Member, Audit committee and Nominations
Committee; Chairman, Remuneration committee.
Applied for Taiw an SE listing April2017.
Feb 2016 - present
The George Institute for Global Health
(University of Sydney) – Advisory Board Member
(SmartGenRx Pty Ltd)
Provide guidance and recommendations to Board of
SmartGenRx regarding research and
commercialization of products.
Oct 2015 - present
JANK Howden Pty Ltd - Director Family Company - Strategic and Leadership
Consulting
Feb 2015 – present
Previous Directorships
Astra Pharmaceuticals (Thailand,Singapore,
Malaysia, The Philippines)
Director Jan 1996 – Oct 1998
Astra Pharmaceuticals (India) Pte Ltd Director – listed Mumbai Stock Exchange Nov 2002 – Oct 2006
Astra Wuxi Pharmaceuticals Ltd. China Director Nov 2002 – Oct 2006
IMS Health (Singapore) Pte Ltd Director May 2007 – Aug 2008
Wirra Holdings P/L, Australia Director Sept 2008 – Feb 2015
Wirra International Holdings Pte Ltd, Singapore Director Sept 2008 – Feb 2015
Wirra International Bidco Pte Ltd, Singapore Director Dec 2011 – Feb 2015

2. Wirra Operations Pty Ltd, Australia Director Dec 2011 – Feb 2015
Wirra IP Pty Ltd, Australia Director Dec 2011 – Feb 2015
iNova Pharmaceuticals (Australia) Pty Ltd CEO, Director Sept 2008 – Feb 2015
iNova Pharmaceuticals (Singapore) Pte Ltd Director Sept 2008 – Feb 2015
iNova Pharmaceuticals (Hong Kong) Ltd Director Sept 2008 – Feb 2015
iNova Pharmaceuticals (Pty) Ltd. Malaysia Director Sept 2008 – Feb 2015
iNova Pharmaceuticals (Thailand) Ltd Director Sept 2008 – Feb 2015
iNova Pharmaceuticals (New Zealand) Ltd Director Sept 2008 – Feb 2015
iNova Pharmaceuticals Philippines,Inc, Director Sept 2008 – Feb 2015
iNova Sub Pty Ltd, Australia Director Dec 2011 – Feb 2015
Valeant Pharmaceuticals Australasia Pty Ltd Director Jan 2012 – Feb 2015
Euvipharm Pharmaceutical JointStock Company
– Vietnam
Director July 2013 – Feb 2015
Bausch & Lomb Philippines,Inc. Director Aug 2013 – Feb 2015
Bausch & Lomb (Singapore) Pte Ltd Director Aug 2013 – Feb 2015
Bausch & Lomb Eyecare (India) Pte Ltd Director Aug 2013 – Feb 2015
Bausch & Lomb (Malaysia) Sdn Bhd Director Aug 2013 – Feb 2015
Bausch & Lomb (South Africa) (Pty) Ltd Director Aug 2013 – Feb 2015
Bausch & Lomb (Thailand) Ltd Director Aug 2013 – Feb 2015
PT Bausch & Lomb Indonesia Director Aug 2013 – Feb 2015
PT Armoxindo Farma - Indonesia Director July 2014 – Feb 2015
Soflens (Pty) Ltd – South Africa Director Aug 2013 – Feb 2015
Technolas (Singapore) Pte Ltd Director Dec 2013 – Feb 2015
Technolas (Hong Kong) Ltd Director Dec 2013 – Feb 2015
Solta Medical (Singapore) Pte Ltd Director Dec 2013 – Feb 2015
Mandalay Apartments Body Corporate,Port
Douglas,Australia
Chairman Jan 2009 – Nov 2011

3. Education
Bachelor of Science, University of New England,NSW,Australia
Masters of Commerce, University of NSW, Australia
Graduate Australian Institute of Company Directors - Company Directors Course
Skills and Attributes
 Proven cross-culturaland cross-functionalleadership skills in Asia, Australia, Japan and Europe
 A track record of developing and delivering profitable growth strategies with diverse teams across
many countries.
 Significant experience in merging organisations and achieving difficult synergy targets
 High levelpersonaland professionalethics coupled with pragmatism, enthusiasm,energy and
motivation to succeed.
 A strong people managerwho prides himself on developing people to their optimalpotential
Executive Experience
iNova Pharmaceuticals Pty Ltd – CEO
Singapore (2012-15) and Sydney (2008-12)
iNova Pharmaceuticals w as created fromthe
acquisition of 3M Pharmaceuticals Asia Pacific and
Africa by Private Equity. Revenues at acquisition w ere
A$118m w ith a manufacturing facility and head office
in Sydney. iNova w as sold to Valeant Pharmaceuticals
in 2011 w ith revenues of A$185mand staff of over
450. iNova HQ w as relocated to Singapore in 2012
and key management w ere retained through the Earn
Out period until 2015. Director on 23 iNova / Valeant
Boards across Asia Pacific. Revenue grew to over
US$500m through organic grow th and acquisitions.
Aug 2008 – Feb 2015
IMS Health – Regional President,Asia Pacific
(Singapore)
With offices in 16 countries in the region IMS employed
over 1,000 people w ith revenues of US$110min 2007
and grow th of over30% in the consulting business.
Focus w as on developing the opportunities for
customers in China, India, Korea and Australia.
Regular consulting to multinational pharmaceutical
customers on their regional strategies and market
trends, plus speaking engagements at regional forums.
Jan 2007 – Aug 2008
AstraZeneca – Regional Vice President,Asia
Pacific and Sth Africa (Singapore)
Responsible for 16 countries, including 6,200 staff and
revenues of US$1.4 billion. Period of rapid grow th,
mostly due to expansion in China.
Oct 2002 – Nov 2006
Quintiles Transnational – Regional President,
Europe (London)
Focus w as to merge all Quintiles European operations
in 32 countries w ith 6,600 staff into one organization.
Sales turnover increased to over US$660m and
profitability improved from<2% to 10+% w ithin 2 years.
2000 - 2002
Quintiles Transnational – Regional President,
Asia Pacific and Sth Africa (Singapore)
Launched pharmaceuticalsales outsourcing business,
Innovex, in Asia, Africa and Australia. Merged
Quintiles businesses, including the contract clinical
research organization, into one group in Asia Pacific
and Japan.
1998 - 2000
Astra Pharmaceuticals (Sydney, Sweden, Various career roles based in Sydney, Sw eden and 1982 - 1998

4. Singapore) Singapore – International Product Management,
Regional Marketing, Management and Sales roles
Referees available on request